Mental health · New York
Mental health studies in New York
117 studies have at least one recruiting site in New York. Mental health research includes studies of depression, anxiety, PTSD, bipolar disorder, schizophrenia and ADHD, testing medicines, devices and talk therapies.
117 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
Axsome Therapeutics, Inc.
- Location
- Staten Island, NY + 28 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
Axsome Therapeutics, Inc.
- Location
- Staten Island, NY + 27 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Draig Therapeutics Ltd
- Location
- New York, NY + 18 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study of Brenipatide in Adult Participants With Schizophrenia
Eli Lilly and Company
- Location
- New York, NY + 31 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 3
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
- Location
- The Bronx, NY + 28 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Seaport Therapeutics
- Location
- Brooklyn, NY + 26 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
ACADIA Pharmaceuticals Inc.
- Location
- Brooklyn, NY + 23 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
- Location
- New York, NY + 31 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Brooklyn, NY + 33 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
MapLight Therapeutics
- Location
- New York, NY + 32 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Commack, NY + 27 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Commack, NY + 17 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 2
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
Neurocrine Biosciences
- Location
- Staten Island, NY + 10 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)
Intra-Cellular Therapies, Inc.
- Location
- Brooklyn, NY + 2 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
SAINT in Postpartum Depression (PPD)
Magnus Medical
- Location
- New York, NY + 3 other US sites
- Eligibility basics
- Ages 18–45 · Women only
- RecruitingPhase 1
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Janssen Research & Development, LLC
- Location
- Cedarhurst, NY + 7 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies, Inc.
- Location
- Brooklyn, NY + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc.
- Location
- New York, NY + 46 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- New York, NY + 33 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.
- Location
- Brooklyn, NY + 24 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Janssen Research & Development, LLC
- Location
- Brooklyn, NY + 41 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.
- Location
- Brooklyn, NY + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Cedarhurst, NY + 44 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Cedarhurst, NY + 18 other US sites
- Eligibility basics
- Ages 18–65
Who these studies look for
Studies usually require a confirmed diagnosis and stable circumstances, and they monitor safety closely. If you are in crisis, contact a crisis line or emergency services rather than a study.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Will joining affect my current treatment?
Some studies require changes to medicines, which the study team manages; others add to your usual care. Talk to your own clinician before making any change.